Eye Health

Clobetasol propionate ophthalmic suspension 0.05% is the first ophthalmic clobetasol propionate product approved by the FDA and is the first new ophthalmic steroid on the market in over 15 years.

Maintaining the structure and function of antibody biologics like faricimab is critical for their administration via intravitreal injection (IVI), a common treatment approach for retinal diseases.

The company that developed the treatment said it will benefit "millions" of patients.

A recent study showed a link between menopause and increased glaucoma risk, with estrogen-based treatment being a possible solution.

The study could lead to early diagnosis and treatment of age-related macular degeneration.

The researchers reported that there was no significant difference in the age-related macular degeneration prevalence among the 3 study groups.

According to the company, clinical outcomes for 78 dry eye patients treated at a single center, the Cleveland Eye Clinic, showcased the duration of efficacy of a single, first-time treatment of MGD using the TearCare System.

Mount Sinai study is the first to identify that heart attack, stroke and heart failure are linked to a specific type of age-related macular degeneration.

According to a study, use is linked to a lower prevalence of age-related macular degeneration in European populations.

According to NEXGEL, the patch is expected be available for ophthalmologists to offer to their patients in the first half of 2023.

The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.

Using 7-methylxanthine may be key to slowing myopia in pediatric cases.

Patients who received the chemotherapies paclitaxel and docetaxel were at an increased risk of adverse events of the eye.

ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.

The debate continues about the protective effect of eyeglasses against contracting the COVID-19 virus. Researchers from Denmark reported that their results were inconclusive regarding whether wearing eyeglasses is linked with a decreased risk of COVID-19 infections.

The research points to the importance of isolating offending organism.

The guidance comes as a result of an increase in eye injury.

Oyster Point Pharma Inc. announced that the largest Medicare pharmacy benefit manager in the United States will add its varenicline solution nasal spray for the treatment of dry eye.

A meta-analysis has found that depression and anxiety are significantly correlated with dry eye disease symptoms but not to dry eye disease signs.

A literature review finds that glaucoma care changed for the better during the COVID-19 pandemic.

New research examines the disparities in vision loss in glaucoma cases.

Cimerli can be used for all 5 indications. No information on pricing has been released.

Oyster Point Pharma Inc. this week announced the expansion of patient access to varenicline solution (Tyrvaya) nasal spray.

Research examines whether a step-approach with treatment for macular edema produces positive results.

The pipeline for eye health is full of potential therapies. Here's a look at 4 that may be available in the near future.

The price of the biosimilar may also be persuasive for patients.

The drug is a potential new therapy for dry eye disease with a novel mechanism of action.